-

SpineGuard: Official Launch of Three New PediGuard® Models During the Annual Scoliosis Meeting in China

Presentation of PediGuard in plenary session

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:

SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announced the official launch of the newly cleared Curved and XS PediGuard models, in Nanjing (China), during the 2026 Chinese Scoliosis Annual Meeting in conjunction with French Spine Society. PediGuard has been highlighted by Professor Helton Defino from Ribeiro Preto (Brazil) during his lecture in plenary session.

Patricia Lempereur, VP of Sales and Marketing at SpineGuard, said: “The new versions of the PediGuard recently approved in China and showcased at XinRong Medical booth, created a great interest among the surgeons, especially the curved version. They can see a real benefit in scoliosis surgery where the vertebral anatomy can be complex. The first evaluation surgeries have already been performed in China with a great success. This congress hosted by Professor Qiu was the opportunity to reinforce our collaboration with our Chinese commercial partner.”

David Han, Board Director at XinRong Medical, added: “We are excited to launch new models of PediGuard with SpineGuard. The new models are great extensions to the current lineup, and they represent originality and continuous innovation of PediGuard. XinRong Medical will deepen our collaboration with SpineGuard and further explore the opportunities for the DSG technology on the Chinese market”.

About SpineGuard®
Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices embedding its technology. Over 110,000 surgical procedures have been secured worldwide thanks to DSG® and 39 studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard is expanding the scope of its DSG® technology to the treatment of scoliosis via anterior approach, sacroiliac joint fusion, dental implantology and innovations such as the « smart » pedicle screw and power drill or surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives. For further information, visit www.spineguard.com

Disclaimer
The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Anne-Charlotte Millard
CFO
Tél. : 01 45 18 45 19
ac.millard@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin
Tel: +33 1 44 71 94 94
spineguard@newcap.eu

SpineGuard

BOURSE:ALSGD

Release Versions

Contacts

SpineGuard
Pierre Jérôme
CEO & Chairman
Tel: +33 1 45 18 45 19
p.jerome@spineguard.com

SpineGuard
Anne-Charlotte Millard
CFO
Tél. : 01 45 18 45 19
ac.millard@spineguard.com

NewCap
Investor Relations & Financial Communication
Mathilde Bohin
Tel: +33 1 44 71 94 94
spineguard@newcap.eu

More News From SpineGuard

SpineGuard and Omnia Medical Complete US Asset Transfer and Enter Exclusive Distribution Agreement for PediGuard®

MORGANTOWN, W. Va. & BOULDER, Colo. & PARIS--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 – ALSGD), an innovative company specializing in Dynamic Surgical Guidance (DSG®) technology to enhance the safety and efficiency of bone implant placement, and Omnia Medical, an orthopedic implant company focused on innovative spine and sacroiliac solutions, today announced the completion of the transfer of SpineGuard Inc assets and the execution of an exclusive distribution U.S. distribution...

SpineGuard Announces Full-Year 2025 Financial Results, First Quarter 2026 Sales, and the Set-Up of a Bond Financing

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, today announces its full-year 2025 financial results for the year ended December 31, 2025, as approved by the Board of Directors on April 07, 2026, its first quarter 2026 sales, as well as the completion of a bond financing of up to €1 million. 2025 Financia...

SpineGuard Announces the Full Settlement of the Norgine and Harbert European Growth Bond Issues

PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 – ALSGD, PEA-PME eligible), an innovative company deploying its digital surgical guidance (DSG®) technology—which measures tissue electrical conductivity locally in real time to ensure the safe and simplified placement of bone implants—announced today the full repayment of its bonds issued to Norgine and Harbert European Growth (now Claret Capital Partners). Anne-Charlotte Millard, Chief Financial Officer of Spin...
Back to Newsroom